<DOC>
	<DOCNO>NCT00239330</DOCNO>
	<brief_summary>The primary objective study compare efficacy rosuvastatin 10 mg atorvastatin 10 mg assessment percentage subject reach EAS LDL-C target goal 12 week therapy .</brief_summary>
	<brief_title>Direct Statin Comparison LDL-C Values : Evaluation Rosuvastatin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male female subject , age &gt; 18 year Primary hypercholesterolaemia CV risk &gt; 20 % ( defined European Guidelines ) and/or type II diabetes and/or history CHD establish atherosclerotic disease . Subjects may lipidlowering therapy naïve treat min . 4 week 'start ' dose lipidlowering therapy , ineffective . Naïve subject must complete 12weeks dietary counsel visit . Known heterozygous homozygous familial hypercholesterolaemia know type III hyperlipoproteinaemia ( familial dysbetalipoproteinaemia ) . Documented secondary hypercholesterolaemia cause name inclusion criterion 3 . Serious unstable medical condition Statin contraindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>high blood cholesterol level</keyword>
</DOC>